Literature DB >> 6202388

Salvage therapy of aggressive non-Hodgkin's lymphoma with a combination of vinblastine, bleomycin, and cisplatin.

M P Corder, G H Clamon.   

Abstract

Thirteen patients with aggressive histologic types of non-Hodgkin's lymphoma had failed to respond or relapsed after intensive polychemotherapy of curative intent. They were treated with a combination of vinblastine, bleomycin, and cisplatin. All were Stage III or IV, and eight had systemic symptoms. There were five objective partial remissions, and no complete remissions. The Kaplan-Meier 50% survival estimate is 5 months from initiation of the salvage chemotherapy. Seven of 13 patients had grade II nausea and vomiting, and 7 had nadir platelet counts less than 70,000/mm3. All had significant anemia. There were two episodes of sepsis, and two patients had pulmonary and nephrotoxicity. The program is not effective in this situation, and is quite toxic.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6202388     DOI: 10.1002/1097-0142(19840715)54:2<202::aid-cncr2820540204>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  2 in total

1.  Treatment of resistant non-Hodgkin's lymphomas with cisplatin, etoposide, and bleomycin.

Authors:  P Comella; G Abate; G Di Finizio; A Daponte; D Zarrilli
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Cisplatin, VP-16-213 and MGBG (methylglyoxal bis guanylhydrazone) combination chemotherapy in refractory lymphoma, a phase II study.

Authors:  L Dabich; M K Liepman
Journal:  Invest New Drugs       Date:  1988-09       Impact factor: 3.850

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.